Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement | Adolescent Medicine | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.237.138.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 4,654
Citations 0
US Preventive Services Task Force
Recommendation Statement
November 10, 2020

Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force
JAMA. 2020;324(18):1878-1883. doi:10.1001/jama.2020.20122
Abstract

Importance  Prevalence of hypertension (both primary and secondary) in children and adolescents in the US ranges from 3% to 4%. Primary hypertension in children and adolescents occurs primarily in children older than 13 years and has no known cause but is associated with several risk factors, including family history and higher body mass index. Secondary hypertension occurs primarily in younger children and is most commonly caused by genetic disorders, renal disease, endocrine disorders, or cardiovascular abnormalities.

Objective  To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on the benefits and harms of screening, test accuracy, the effectiveness and harms of treatment, and the association between hypertension and markers of cardiovascular disease in childhood and adulthood.

Population  This recommendation statement applies to children and adolescents aged 3 to 18 years not known to have hypertension or who are asymptomatic.

Evidence Assessment  The USPSTF concludes that the evidence to support screening for high blood pressure in children and adolescents is insufficient and that the balance of benefits and harms cannot be determined.

Recommendation  The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for high blood pressure in children and adolescents. (I statement)

×